Clinical course of intestinal Behcet's disease during the first five years

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 496-503

  Jung, Yoon Suk ^a,b   Cheon, Jae Hee ^a   Park, Soo Jung ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Clinical course; High disease activity; Intestinal Behcet's disease; Prognostic factors

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CORTICOSTEROID; GASTROINTESTINAL AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BEHCET DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTESTINAL BEHCET DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RELAPSE; REMISSION; ENTEROPATHY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHCET SYNDROME; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL DISEASES; MALE; MESALAMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SULFASALAZINE;

MLCS; MLOWN;

EID: 84876324034     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2351-9     Document Type: Article

References (23)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341:1284-1291.
2. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol. 2007;42:737-745.
3. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492-2499.
4. Cheon JH, Celik AF, Kim WH. Behçet's disease: gastrointestinal involvement. In: Yazici Y, Yazici H, eds. Behçet's syndrome. New York: Springer; 2010:165-188.
5. Ebert EC. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci. 2009;54:201-207.
6. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behcet's disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum. 1981;24:103-106.
7. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2011;17:1594-1602.
8. Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn's disease. Inflamm Bowel Dis. 2005;11:765-777.
9. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis. 2011;17:605-613.
10. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2012;18:750-757.
11. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. Inflamm Bowel Dis. 2012;18(6):1064-1071.
12. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behçet's disease. Inflamm Bowel Dis. 2001;7:243-249.
13. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
14. Solberg IC, Vatn MH, Hie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438.
15. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42:602-610.
16. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543-550.
17. Moum B. Medical treatment: does it influence the natural course of inflammatory bowel disease? Eur J Intern Med. 2000;11:197-203.
18. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200-1206.
19. Choi IJ, Kim JS, Park MJ, et al. Evaluation of prognosis and cumulative operation rate of intestinal Behcet's disease in comparison with Crohn's disease. Korean J Gastroenterol. 2000;36:504-514.
20. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
21. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
22. Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114-1122.
23. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963.